| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| G A Thakur, S P Nikas, C Li, A Makriyanni. Structural requirements for cannabinoid receptor probes. Handbook of experimental pharmacology. issue 168. 2006-04-19. PMID:16596776. |
the discovery and cloning of cb1 and cb2, the two known g(i/o) protein-coupled cannabinoid receptors, as well as the isolation and characterization of two families of endogenous cannabinergic ligands represented by arachidonoylethanolamide (anandamide) and 2-arachidonoylglycerol (2-ag), have opened new horizons in this newly discovered field of biology. |
2006-04-19 |
2023-08-12 |
Not clear |
| P H Reggi. Cannabinoid receptors and their ligands: ligand-ligand and ligand-receptor modeling approaches. Handbook of experimental pharmacology. issue 168. 2006-04-19. PMID:16596777. |
the cannabinoid cb1 and cb2 receptors belong to the class a, rhodopsin-like family of gpcrs. |
2006-04-19 |
2023-08-12 |
Not clear |
| C W Vaughan, M J Christi. Retrograde signalling by endocannabinoids. Handbook of experimental pharmacology. issue 168. 2006-04-19. PMID:16596781. |
the cannabinoid neurotransmitter system comprises cannabinoid g protein-coupled membrane receptors (cb1 and cb2), endogenous cannabinoids (endocannabinoids), as well as mechanisms for their synthesis, membrane transport and metabolism. |
2006-04-19 |
2023-08-12 |
Not clear |
| G A Cabral, A Staa. Effects on the immune system. Handbook of experimental pharmacology. issue 168. 2006-04-19. PMID:16596782. |
first, cannabinoids may signal through the cannabinoid receptors cb1 and cb2. |
2006-04-19 |
2023-08-12 |
Not clear |
| J Fernández-Ruiz, S Gonzále. Cannabinoid control of motor function at the basal ganglia. Handbook of experimental pharmacology. issue 168. 2006-04-19. PMID:16596785. |
this finding is supported by three-fold evidence: (1) the abundance of the cannabinoid cb1 receptor subtype, but also of cb2 and vanilloid vr1 receptors, as well as of endocannabinoids in the basal ganglia and the cerebellum, the areas that control movement; (2) the demonstration of a powerful action, mostly of an inhibitory nature, of plant-derived, synthetic, and endogenous cannabinoids on motor activity, exerted by modulating the activity of various classic neurotransmitters; and (3) the occurrence of marked changes in endocannabinoid transmission in the basal ganglia of humans affected by several motor disorders, an event corroborated in animal models of these neurological diseases. |
2006-04-19 |
2023-08-12 |
Not clear |
| J M Walker, A G Hohman. Cannabinoid mechanisms of pain suppression. Handbook of experimental pharmacology. issue 168. 2006-04-19. PMID:16596786. |
these studies provide insight into the functional roles of cannabinoid cb1 (cb1r) and cb2 (cb2r) receptor subtypes in cannabinoid antinociceptive mechanisms, as revealed in animal models of acute and persistent pain. |
2006-04-19 |
2023-08-12 |
human |
| Daniele Piomell. The endocannabinoid system: a drug discovery perspective. Current opinion in investigational drugs (London, England : 2000). vol 6. issue 7. 2006-04-18. PMID:16044662. |
they are produced by cells in the brain and other tissues and combine with two subtypes of g protein-coupled cannabinoid receptors, cb1 and cb2. |
2006-04-18 |
2023-08-12 |
Not clear |
| Alyson Fox, Stuart Beva. Therapeutic potential of cannabinoid receptor agonists as analgesic agents. Expert opinion on investigational drugs. vol 14. issue 6. 2006-04-14. PMID:16004597. |
animal studies show that although these side effects are mediated via central cannabinoid type 1 (cb(1)) receptors, the analgesic activity in chronic pain states may be mediated via spinal cb(1) and potentially cb(2) receptors, as well as peripheral cb(1) and cb2 receptors on sensory nerves or immune cells. |
2006-04-14 |
2023-08-12 |
Not clear |
| Ken Macki. Cannabinoid receptors as therapeutic targets. Annual review of pharmacology and toxicology. vol 46. 2006-04-12. PMID:16402900. |
cb1 and cb2 cannabinoid receptors are the primary targets of endogenous cannabinoids (endocannabinoids). |
2006-04-12 |
2023-08-12 |
Not clear |
| Garry Milman, Yehoshua Maor, Saleh Abu-Lafi, Michal Horowitz, Ruth Gallily, Sandor Batkai, Fong-Ming Mo, Laszlo Offertaler, Pal Pacher, George Kunos, Raphael Mechoula. N-arachidonoyl L-serine, an endocannabinoid-like brain constituent with vasodilatory properties. Proceedings of the National Academy of Sciences of the United States of America. vol 103. issue 7. 2006-04-07. PMID:16467152. |
contrary to anandamide, ara-s binds very weakly to cannabinoid cb1 and cb2 or vanilloid trpv1 (transient receptor potential vanilloid 1) receptors. |
2006-04-07 |
2023-08-12 |
mouse |
| Tiziano Tuccinardi, Pier Luigi Ferrarini, Clementina Manera, Gabriella Ortore, Giuseppe Saccomanni, Adriano Martinell. Cannabinoid CB2/CB1 selectivity. Receptor modeling and automated docking analysis. Journal of medicinal chemistry. vol 49. issue 3. 2006-03-29. PMID:16451064. |
three-dimensional models of the cb1 and cb2 cannabinoid receptors were constructed by means of a molecular modeling procedure, using the x-ray structure of bovine rhodopsin as the initial template, and taking into account the available site-directed mutagenesis data. |
2006-03-29 |
2023-08-12 |
cattle |
| Yumiko Nakajima, Yasushi Furuichi, Kamal Krishna Biswas, Teruto Hashiguchi, Ko-ichi Kawahara, Kazuyo Yamaji, Tomonori Uchimura, Yuichi Izumi, Ikuro Maruyam. Endocannabinoid, anandamide in gingival tissue regulates the periodontal inflammation through NF-kappaB pathway inhibition. FEBS letters. vol 580. issue 2. 2006-03-21. PMID:16406050. |
the cannabinoid receptors cb1 and cb2 were expressed by human gingival fibroblasts (hgfs), and markedly upregulated under pathological conditions. |
2006-03-21 |
2023-08-12 |
human |
| Giovanni Appendino, Maria Grazia Cascio, Sara Bacchiega, Aniello Schiano Moriello, Alberto Minassi, Adèle Thomas, Ruth Ross, Roger Pertwee, Luciano De Petrocellis, Vincenzo Di Marz. First "hybrid" ligands of vanilloid TRPV1 and cannabinoid CB2 receptors and non-polyunsaturated fatty acid-derived CB2-selective ligands. FEBS letters. vol 580. issue 2. 2006-03-21. PMID:16406364. |
first "hybrid" ligands of vanilloid trpv1 and cannabinoid cb2 receptors and non-polyunsaturated fatty acid-derived cb2-selective ligands. |
2006-03-21 |
2023-08-12 |
human |
| Jian-Zhong Chen, Xiu-Wen Han, Qian Liu, Alexandros Makriyannis, Junmei Wang, Xiang-Qun Xi. 3D-QSAR studies of arylpyrazole antagonists of cannabinoid receptor subtypes CB1 and CB2. A combined NMR and CoMFA approach. Journal of medicinal chemistry. vol 49. issue 2. 2006-03-21. PMID:16420048. |
the present work focuses on the study of the three-dimensional (3d) structural requirements for selective antagonist activity of arylpyrazole compounds at the cannabinoid cb1 and cb2 receptors. |
2006-03-21 |
2023-08-12 |
Not clear |
| Pablo Juan-Picó, Esther Fuentes, F Javier Bermúdez-Silva, F Javier Díaz-Molina, Cristina Ripoll, Fernando Rodríguez de Fonseca, Angel Nada. Cannabinoid receptors regulate Ca(2+) signals and insulin secretion in pancreatic beta-cell. Cell calcium. vol 39. issue 2. 2006-03-20. PMID:16321437. |
the endocannabinoid 2-arachidonylglycerol (2-ag) through cb2 receptors regulates [ca(2+)](i) signals in beta-cells and as a consequence, it decreases insulin secretion. |
2006-03-20 |
2023-08-12 |
Not clear |
| Uberto Pagotto, Giovanni Marsicano, Daniela Cota, Beat Lutz, Renato Pasqual. The emerging role of the endocannabinoid system in endocrine regulation and energy balance. Endocrine reviews. vol 27. issue 1. 2006-03-16. PMID:16306385. |
cannabinoid receptors, named cb1 receptor and cb2 receptor, first discovered as the molecular targets of the psychotropic component of the plant cannabis sativa, participate in the physiological modulation of many central and peripheral functions. |
2006-03-16 |
2023-08-12 |
Not clear |
| Garth T Whiteside, Susan L Gottshall, Jamie M Boulet, Suzanne M Chaffer, James E Harrison, Michelle S Pearson, Paul I Turchin, Lilly Mark, Augusta E Garrison, Kenneth J Valenzan. A role for cannabinoid receptors, but not endogenous opioids, in the antinociceptive activity of the CB2-selective agonist, GW405833. European journal of pharmacology. vol 528. issue 1-3. 2006-03-09. PMID:16316650. |
several recent reports have demonstrated a role for selective cannabinoid cb2 receptor agonists in pain modulation, showing both analgesic and antihyperalgesic activities. |
2006-03-09 |
2023-08-12 |
mouse |
| Garth T Whiteside, Susan L Gottshall, Jamie M Boulet, Suzanne M Chaffer, James E Harrison, Michelle S Pearson, Paul I Turchin, Lilly Mark, Augusta E Garrison, Kenneth J Valenzan. A role for cannabinoid receptors, but not endogenous opioids, in the antinociceptive activity of the CB2-selective agonist, GW405833. European journal of pharmacology. vol 528. issue 1-3. 2006-03-09. PMID:16316650. |
we have previously reported that administration of the selective cannabinoid cb2 receptor agonist gw405833 (2,3-dichloro-phenyl)-[5-methoxy-2-methyl-3-(2-morpholin-4-yl-ethyl)-indol-1-yl]-methanone) to rats elicits potent and efficacious antihyperalgesic effects against neuropathic and inflammatory pain and, at high dose (100 mg/kg), is analgesic and ataxic [valenzano, k.j., tafesse, l., lee, g., harrison, j.e., boulet, j., gottshall, s.l., mark, l., pearson, m.s., miller, w., shan, s., rabadi, l., rotstheyn, y., chaffer, s.m., turchin, p.i., elsemore, d.a., toth, m., koetzner, l., whiteside, g.t., 2005. |
2006-03-09 |
2023-08-12 |
mouse |
| Garth T Whiteside, Susan L Gottshall, Jamie M Boulet, Suzanne M Chaffer, James E Harrison, Michelle S Pearson, Paul I Turchin, Lilly Mark, Augusta E Garrison, Kenneth J Valenzan. A role for cannabinoid receptors, but not endogenous opioids, in the antinociceptive activity of the CB2-selective agonist, GW405833. European journal of pharmacology. vol 528. issue 1-3. 2006-03-09. PMID:16316650. |
in the current study, we confirm these properties using mouse models and investigate the role of cannabinoid cb2 receptors using knockout animals. |
2006-03-09 |
2023-08-12 |
mouse |
| Garth T Whiteside, Susan L Gottshall, Jamie M Boulet, Suzanne M Chaffer, James E Harrison, Michelle S Pearson, Paul I Turchin, Lilly Mark, Augusta E Garrison, Kenneth J Valenzan. A role for cannabinoid receptors, but not endogenous opioids, in the antinociceptive activity of the CB2-selective agonist, GW405833. European journal of pharmacology. vol 528. issue 1-3. 2006-03-09. PMID:16316650. |
in contrast, gw405833 showed no antihyperalgesic activity against freund's complete adjuvant-mediated inflammatory pain in cannabinoid cb2 receptor knockout mice. |
2006-03-09 |
2023-08-12 |
mouse |